Get detailed information on Apixaban, including pronunciation ... avoid coadministration with strong dual inhibitors. • Discontinuing eliquis in patients without adequate continuous ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place this week ...

Perosphere (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today announced Laura J. Seplavy, MS, joins its team as ...

DANBURY, Conn., Oct. 30, 2024 /PRNewswire/ -- Perosphere (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics ...

After the stroke, 83.8% were put on antiplatelet therapy. The DOAC initiated for the study was most commonly apixaban ...

Alongside this were increased operational revenues of 9% for Eliquis (apixaban), 28% for Xtandi (enzalutamide), 45% for Vydura (rimegepant sulfate), and 63% for Pfizer’s Vyndagel family ...

Alongside this were increased operational revenues of 9% for Eliquis (apixaban), 28% for Xtandi (enzalutamide), 45% for Vydura (rimegepant sulfate), and 63% for Pfizer’s Vyndagel family (tafamidis) ...

A senior official of the Pharmexcil said drugs such as Merck's Pembrolizumab (Keytruda) whose revenue were at USD 25 billion and Bristol-Myers Squibb's Eliquis (Apixaban)-USD 12 billion, among others ...

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.